JP2020512978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512978A5 JP2020512978A5 JP2019553167A JP2019553167A JP2020512978A5 JP 2020512978 A5 JP2020512978 A5 JP 2020512978A5 JP 2019553167 A JP2019553167 A JP 2019553167A JP 2019553167 A JP2019553167 A JP 2019553167A JP 2020512978 A5 JP2020512978 A5 JP 2020512978A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- cancer
- αvβ3
- avb3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 156
- 229920001184 polypeptide Polymers 0.000 claims description 134
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 134
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 134
- 201000011510 cancer Diseases 0.000 claims description 96
- 210000004027 cell Anatomy 0.000 claims description 45
- 210000002540 macrophage Anatomy 0.000 claims description 40
- 210000000130 stem cell Anatomy 0.000 claims description 27
- 210000004881 tumor cell Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 13
- 102000006495 integrins Human genes 0.000 claims description 12
- 108010044426 integrins Proteins 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 230000028709 inflammatory response Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000004614 tumor growth Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 229940122924 Src inhibitor Drugs 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000005889 cellular cytotoxicity Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229940020967 gemzar Drugs 0.000 claims description 2
- 238000011577 humanized mouse model Methods 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940028652 abraxane Drugs 0.000 claims 1
- 229940082789 erbitux Drugs 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 229940120982 tarceva Drugs 0.000 claims 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims 1
- 229940094060 tykerb Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021054730A JP2021095423A (ja) | 2017-03-31 | 2021-03-29 | アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479768P | 2017-03-31 | 2017-03-31 | |
| US62/479,768 | 2017-03-31 | ||
| PCT/US2018/025470 WO2018183894A1 (en) | 2017-03-31 | 2018-03-30 | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021054730A Division JP2021095423A (ja) | 2017-03-31 | 2021-03-29 | アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512978A JP2020512978A (ja) | 2020-04-30 |
| JP2020512978A5 true JP2020512978A5 (enExample) | 2021-05-06 |
Family
ID=63676868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553167A Pending JP2020512978A (ja) | 2017-03-31 | 2018-03-30 | アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 |
| JP2021054730A Pending JP2021095423A (ja) | 2017-03-31 | 2021-03-29 | アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021054730A Pending JP2021095423A (ja) | 2017-03-31 | 2021-03-29 | アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200109205A1 (enExample) |
| EP (2) | EP4353318A3 (enExample) |
| JP (2) | JP2020512978A (enExample) |
| KR (1) | KR102630070B1 (enExample) |
| CN (1) | CN110662559A (enExample) |
| AU (1) | AU2018243670B2 (enExample) |
| BR (1) | BR112019020451A2 (enExample) |
| CA (1) | CA3058458A1 (enExample) |
| EA (1) | EA201992326A1 (enExample) |
| IL (1) | IL269746A (enExample) |
| MX (1) | MX2019011717A (enExample) |
| WO (1) | WO2018183894A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021015336A1 (ko) * | 2019-07-24 | 2021-01-28 | 가톨릭대학교 산학협력단 | αVβ3 인테그린 표적 단일 도메인 항체 |
| BR112022001273A2 (pt) * | 2019-08-02 | 2022-06-07 | Univ California | Composições e métodos para direcionar e matar células tronco cancerosas (cscs) positivas para alfa-v beta-3 (avss3) (cscs) e tratar cânceres metastáticos e resistentes a fármacos |
| US20230140868A1 (en) * | 2020-04-23 | 2023-05-11 | Alpha Beta Holdings, Llc | Compositions and methods for treating cancer |
| CN112626118B (zh) * | 2020-11-12 | 2023-06-23 | 清华-伯克利深圳学院筹备办公室 | 细胞株及其应用 |
| WO2023056326A1 (en) * | 2021-09-30 | 2023-04-06 | Alpha Beta Holdings, Llc | Compositions and methods for treating cancer |
| CN115960160B (zh) * | 2021-10-12 | 2024-07-16 | 南京大学 | 活细胞膜整合素αvβ3聚糖的原位糖链延长方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
| SK163598A3 (en) * | 1996-05-31 | 1999-06-11 | Scripps Research Inst | Methods and compositions useful for inhibition of angiogenesis |
| US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| CN1261791A (zh) | 1997-07-02 | 2000-08-02 | Sdg有限公司 | 诊断或治疗用途的靶向脂质体构建物 |
| RU2236251C2 (ru) * | 1999-02-12 | 2004-09-20 | Дзе Скриппс Рисерч Инститьют | Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии |
| ATE328582T1 (de) | 1999-04-23 | 2006-06-15 | Mitsubishi Chem Corp | Antikörper und polyalkylenglycol gebundenes liposom |
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US7858117B2 (en) | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| JP2005533001A (ja) * | 2002-03-04 | 2005-11-04 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法 |
| EP1547581A1 (en) | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
| KR20060123384A (ko) | 2003-12-24 | 2006-12-01 | 가부시키가이샤 엘티티 바이오파마 | 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제 |
| JP2007526322A (ja) | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| US20070082042A1 (en) | 2004-08-06 | 2007-04-12 | Deok-Hoon Park | Multiple-layered liposome and preparation method thereof |
| AU2005277641A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| CN101506238B (zh) * | 2005-06-30 | 2013-11-06 | 森托科尔公司 | 具有提高治疗活性的方法和成分 |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| US20080088046A1 (en) | 2006-10-13 | 2008-04-17 | Steffen Panzner | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| WO2007059195A1 (en) * | 2005-11-14 | 2007-05-24 | University Of Southern California | Integrin-binding small molecules |
| US20080089928A1 (en) | 2006-06-13 | 2008-04-17 | Stavroula Sofou | Liposome drug carriers with ph-sensitivity |
| US20110319335A1 (en) * | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| WO2012167028A2 (en) * | 2011-06-02 | 2012-12-06 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition |
| WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| CN106232625B (zh) * | 2013-10-01 | 2020-04-24 | 免疫医疗有限公司 | 治疗和诊断过表达α-V-β-6的癌症的方法 |
| CA2929044A1 (en) * | 2013-11-11 | 2015-05-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
| WO2016100858A1 (en) * | 2014-12-18 | 2016-06-23 | The Regents Of The University Of California | Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype |
| BR112022001273A2 (pt) * | 2019-08-02 | 2022-06-07 | Univ California | Composições e métodos para direcionar e matar células tronco cancerosas (cscs) positivas para alfa-v beta-3 (avss3) (cscs) e tratar cânceres metastáticos e resistentes a fármacos |
-
2018
- 2018-03-30 US US16/499,623 patent/US20200109205A1/en not_active Abandoned
- 2018-03-30 JP JP2019553167A patent/JP2020512978A/ja active Pending
- 2018-03-30 CA CA3058458A patent/CA3058458A1/en active Pending
- 2018-03-30 EA EA201992326A patent/EA201992326A1/ru unknown
- 2018-03-30 KR KR1020197031332A patent/KR102630070B1/ko active Active
- 2018-03-30 WO PCT/US2018/025470 patent/WO2018183894A1/en not_active Ceased
- 2018-03-30 EP EP23203602.0A patent/EP4353318A3/en active Pending
- 2018-03-30 MX MX2019011717A patent/MX2019011717A/es unknown
- 2018-03-30 BR BR112019020451-2A patent/BR112019020451A2/pt unknown
- 2018-03-30 AU AU2018243670A patent/AU2018243670B2/en active Active
- 2018-03-30 EP EP18774300.0A patent/EP3600422B1/en active Active
- 2018-03-30 CN CN201880033739.9A patent/CN110662559A/zh active Pending
-
2019
- 2019-10-02 IL IL26974619A patent/IL269746A/en unknown
-
2021
- 2021-03-29 JP JP2021054730A patent/JP2021095423A/ja active Pending
-
2023
- 2023-10-04 US US18/480,778 patent/US20240067733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI780994B (zh) | 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體 | |
| US20230279096A1 (en) | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer | |
| ES2951650T3 (es) | Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| US20180133180A1 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| JP2017537090A5 (enExample) | ||
| Wu et al. | Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| KR20140053865A (ko) | 항-ｅｒｂｂ3제를 포함하는 조합 요법 | |
| JP2018531278A (ja) | 癌のための併用療法 | |
| JP2018531278A6 (ja) | 癌のための併用療法 | |
| US20220249621A1 (en) | TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS | |
| TWI728400B (zh) | Cd226促效劑抗體 | |
| CN108697801A (zh) | 使用liv1-adc和化学治疗的组合疗法 | |
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| CN110036030A (zh) | 癌症的组合疗法 | |
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| Suder et al. | A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours | |
| US20140079703A1 (en) | Combination therapies comprising anti-erbb3 agents | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| Smith et al. | Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer | |
| CN115227812A (zh) | 抗pd-1抗体联合一线化疗治疗晚期nsclc的用途 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| Toldra et al. | American Association for Cancer Research Virtual Annual Meeting I. April 27-28, 2020 |